Fore Capital LLC Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Fore Capital LLC bought a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the 4th quarter, Holdings Channel.com reports. The fund bought 130,000 shares of the biotechnology company’s stock, valued at approximately $967,000.

Other large investors also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Grifols during the fourth quarter worth about $28,000. GAMMA Investing LLC grew its holdings in Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares in the last quarter. Blue Trust Inc. increased its position in shares of Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,970 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Grifols in the 4th quarter valued at $91,000. Finally, HighTower Advisors LLC lifted its position in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley assumed coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.76 on Thursday. The stock’s 50-day simple moving average is $7.49 and its 200-day simple moving average is $8.15. The firm has a market capitalization of $5.34 billion, a PE ratio of 6.63 and a beta of 0.35. Grifols, S.A. has a fifty-two week low of $5.68 and a fifty-two week high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.